Continuing cariogenic bacterial growth demineralizing dentine beneath a composite filling is the most common cause of tooth restoration failure. Novel composites with antibacterial polylysine (PLS) (0, 4, 6, or 8 wt%) in its filler phase were therefore produced. Remineralising monocalcium phosphate was also included at double the PLS weight. Antibacterial studies involved set composite disc placement in 1% sucrose-supplemented broth containing (UA159). Relative surface bacterial biofilm mass ( = 4) after 24 h was determined by crystal violet-binding. Live/dead bacteria and biofilm thickness ( = 3) were assessed using confocal laser scanning microscopy (CLSM). To understand results and model possible in vivo benefits, cumulative PLS release from discs into water ( = 3) was determined by a ninhydrin assay. Results showed biofilm mass and thickness decreased linearly by 28% and 33%, respectively, upon increasing PLS from 0% to 8%. With 4, 6, and 8 wt% PLS, respectively, biofilm dead bacterial percentages and PLS release at 24 h were 20%, 60%, and 80% and 85, 163, and 241 μg/disc. Furthermore, initial PLS release was proportional to the square root of time and levelled after 1, 2, and 3 months at 13%, 28%, and 42%. This suggested diffusion controlled release from water-exposed composite surface layers of 65, 140, and 210 μm thickness, respectively. In conclusion, increasing PLS release initially in any gaps under the restoration to kill residual bacteria or longer-term following composite/tooth interface damage might help prevent recurrent caries.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564959 | PMC |
http://dx.doi.org/10.3390/jfb11030055 | DOI Listing |
Eur J Pharm Sci
January 2025
Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address:
Premature drug release is the primary hindrance to the effective function of the lyso-thermosensitive liposomes (LTSLs) of doxorubicin (Dox), known as ThermoDox® for the treatment of cancer. Herein, we have optimized LTSLs by using a combination of phospholipids (PLs) with high transition temperatures (Tm) to improve the therapeutic outcome in an assisted ultrasound approach. For this, several Dox LTSLs were prepared using the remote loading method at varying molar ratios (0 to 90%) of DPPC (Tm 41°C) and HSPC (Tm 54.
View Article and Find Full Text PDFBMC Oral Health
January 2025
Faculty of Dentistry, Thammasat University, Pathum Thani, 12120, Thailand.
Background: This study aimed to develop ion-releasing and antibacterial resin-based dental sealants comprising 3 to 6 wt% monocalcium phosphate monohydrate (MCPM, M), 3 to 6 wt% bioactive glass (BAG, B), and 3 to 6 wt% polylysine (PLS, P). The physical properties, mechanical performance, cytotoxicity, and inhibition of S. mutans biofilm by these materials were subsequently evaluated.
View Article and Find Full Text PDFAnn Agric Environ Med
December 2024
Department of Hygiene and Dietetics, Jagiellonian University Medical College, Krakow, Poland.
Introduction And Objective: Considering the complexity of medical discourse, the enormous amount of information, including fake news, it becomes increasingly challenging to develop health literacy among the general population and to ensure efficient communication of scientific findings on the effects of health interventions to various types of recipients. We aimed to gain an in-depth understanding of how the various types of audiences perceive various formats for presenting data from Cochrane systematic reviews (SRs).
Material And Methods: We conducted focus group interviews with university employees, students, pharmacists, patients, caregivers, physicians, and nurses.
Resusc Plus
December 2024
School of Public Health and Preventive Medicine, Monash University, VIC, Australia.
Eur J Pharm Sci
January 2025
Global Analytical Technology Lab, Merck Healthcare KGaA, Frankfurter Straße 250, 64289, Darmstadt, Germany.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!